Company Analysis
Sign in

BioAge Labs, Inc. (BIOA)

Nasdaq: BIOA · Pharmaceutical Preparations · Emeryville, CA · filing with the SEC since 2024
Full chart Alerts Compare
Grade5.6
◀ Past 4.4● Present 6.6▶ Future 5.4
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioAge Labs, Inc.’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 2 in 2024 and 3 in 2023
Applications published
23
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry7
Pharmaceuticals2
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BioAge Labs, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
BioAge Labs, Inc. its own name
US, as the owner printed on each patent
10 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 7, 202512,435,043Inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Sep 23, 202512,421,196Inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Feb 4, 202512,215,087Inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Oct 29, 202412,129,251N-oxide inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Jan 23, 202411,881,311Survival prediction using metabolomic profilesMedical technologyBioAge Labs, Inc.
Oct 17, 202311,787,805N-oxide inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Jul 25, 202311,708,334Inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Jul 18, 202311,702,391Inhibitors of NLRP3 inflammasomeOrganic fine chemistryBioAge Labs, Inc.
Dec 27, 202211,535,661RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofPharmaceuticalsBioAge Labs, Inc.
Feb 9, 202110,913,784RAGE fusion proteins with improved stability and ligand binding affinity and uses thereofPharmaceuticalsBioAge Labs, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0304581INHIBITORS OF NLRP3 INFLAMMASOMEPharmaceuticalsBioAge Labs, Inc. · patent 12,509,459 granted from it
May 15, 20252025/0155452NLRP3 Variants & Library Screen for NLRP3 Inhibitors with the SameAnalysis of biological materialsBioAge Labs, Inc.
Mar 20, 20252025/0092037N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOMEOrganic fine chemistryBioAge Labs, Inc.
Mar 13, 20252025/0084080CRYSTALLINE AND SALT FORMS OF AN NLRP3 INHIBITORPharmaceuticalsBioAge Labs, Inc.
Nov 7, 20242024/0366602COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAINPharmaceuticalsBioAge Labs, Inc.
Aug 1, 20242024/0252493Apelin Receptor Modulators for Treating Age-Related Muscle ConditionsPharmaceuticalsBioAge Labs, Inc.
Apr 18, 20242024/0122926APELIN RECEPTOR MODULATORS FOR TREATING MUSCLE CONDITIONSPharmaceuticalsBioAge Labs, Inc.
Apr 11, 20242024/0116933INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF NLRP3 INFLAMMASOMEOrganic fine chemistryBioAge Labs, Inc.
Mar 28, 20242024/0105340SURVIVAL PREDICTION USING METABOLOMIC PROFILESMedical technologyBioAge Labs, Inc.
Feb 29, 20242024/0067648N-OXIDE INHIBITORS OF NLRP3 INFLAMMASOMEOrganic fine chemistryBioAge Labs, Inc. · patent 12,129,251 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 6 · Organic fine chemistry 5 · Medical technology 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BIOA · research, not advice